Applied BioMath, LLC announces live webinar on Quantitative Systems Pharmacology Modeling (QSPM) in Immuno-oncology

LINCOLN, Mass., March 22, 2016 /PRNewswire/ -- Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug development, today announced an upcoming live webinar:

"Quantitative Systems Pharmacology Modeling (QSPM) Case Study in Immuno-oncology"

to be held on Tuesday, April 12, 2016 at 11am ET/8am PT, hosted by Fierce Markets.

Dr. John Burke, PhD, Co-Founder, President, and CEO of Applied BioMath, will discuss the value of QSPM approaches in drug R&D and present an industry case study in immuno-oncology.   The case study entails developing and interrogating a QSPM of PD-1 and TIM-3. The QSPM provided:

• Biological insights by predicting why dosing regimens are quite similar for two therapeutics targeting PD-1 that have affinities that differ by several orders of magnitude
• Best-in-class profile predictions for PD-1 and TIM-3 dual antagonists

This webinar is ideal for scientists in R&D who want to learn more about how to leverage QSPM to shorten timelines, lower cost, and increase the likelihood of developing best-in-class drugs.

To register, please visit:

www.appliedbiomath.com/webinars

"This webinar will be a great introduction to the potential of systems modeling approaches in drug R&D. I look forward to sharing this case study which demonstrates how incorporating systems modeling into R&D can result in tangible, impactful results in a fairly short timeframe."

Dr. John Burke, PhD, Co-Founder, President, and CEO of Applied BioMath

About Applied BioMath

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug development, helps biotechnology and pharmaceutical companies answer complex, critical Go/No-go decisions in R&D.    Applied BioMath leverages biology, proprietary technology, high-performance computing, and decades of industry experience to help groups better understand their candidate, its best-in-class parameters, competitive advantages, and the best path forward.   Our involvement shortens project timelines, lowers cost, and increases the likelihood of a best-in-class drug.  We provide clarity to complex situations, answer otherwise unanswerable questions, and our approach, when validated in the clinic, is 10x more accurate than traditional methodologies.

Applied BioMath and the Applied BioMath logo are trademarks of Applied BioMath, LLC.

Press contact:
Kristen Zannella
[email protected]

Logo - http://photos.prnewswire.com/prnh/20150915/266672LOGO

SOURCE Applied BioMath

Related Links

http://www.appliedbiomath.com